Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,358.00down ₹7.60 (0.56%)BSE ₹1,357.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,365.60.
29 Oct: open ₹1,357.70, high ₹1,372.50, low ₹1,347.00
52-week range of traded prices to 29 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,09,709 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.96%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,41,23054.3% delivered
Cipla disputes and clarifications
21 filed, newest first.
Jan 2025
17 Jan · Legal
Dec 2024
20 Dec · Legal
2 Dec · Legal
Nov 2024
28 Nov · Legal
Oct 2024
17 Oct · Legal
Feb 2019
18 Feb · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Mylan recalls spray made at Cipla unit". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.18 Feb · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Mylan recalls spray made at Cipla unit ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Mar 2017
Feb 2015
13 Feb · Legal
Exchange has sought clarification from Cipla Limited with respect to recent news item captioned "Cipla to Launch generic of Gilead's Hepatitis C Drug". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
17 Dec · Legal
Exchange has sought clarification from Cipla Limited with respect to recent news item captioned "Novartis drags Cipla to court". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Sep 2014
Apr 2014
Feb 2014
Jan 2011
28 Jan · Legal
Company have received a query from the Financial Daily regarding stake sale by Cipla. In this connection, the Company had categorically denied this news vide letter dated December 20, 2010. The Company would once again like to reiterate that these rumours are absolutely baseless and are purely speculative in nature and the Company has no intention whatsoever to do any stake sale.
Dec 2010
20 Dec · Legal
Company have issued the below statement to wire agencies regarding clarification on Cipla's stake sale. "The speculative news on stake sale of Cipla or any of its brand is baseless and therefore denied."
Jul 2010
9 Jul · Legal
Vide its letter dated July 09, 2010 that "With reference to the news item appearing in today's newspaper titled "Cipla brass to get new shine, CEO to step down". At the outset we would like to inform you that the contents of the news items are speculative. We wish to clarify that Mr. Amar Lulla is on medical leave. The Board is fully seized of the matter and will take appropriate steps as and when needed."